Get the Stockscreener App
32.16
4.18%
1.29
Pre-market:
31.86
-0.30
-0.93%
Indivior Pharmaceuticals Inc stock is traded at $32.16, with a volume of 2.25M.
It is up +4.18% in the last 24 hours and down -6.35% over the past month.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
See More
Previous Close:
$30.87
Open:
$30.41
24h Volume:
2.25M
Relative Volume:
1.01
Market Cap:
$4.02B
Revenue:
$1.24B
Net Income/Loss:
$209.00M
P/E Ratio:
19.37
EPS:
1.6605
Net Cash Flow:
$-94.86M
1W Performance:
-4.37%
1M Performance:
-6.35%
6M Performance:
+30.04%
1Y Performance:
+218.42%
1-Day Range:
$30.33
$32.39
1-Week Range:
$30.33
$35.38
52-Week Range:
$8.64
$38.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Name
Indivior Pharmaceuticals Inc
Sector
Phone
804-379-1090
Address
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
32.16 | 3.86B | 1.24B | 209.00M | -94.86M | 1.6605 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Jul-22-25 | Resumed | Jefferies | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
View All
Indivior Pharmaceuticals Inc Stock (INDV) Latest News
Global Transdermal Skin Patch Market Size, Growth, Trends & - openPR.com
Indivior PLC (NASDAQ:INDV) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Indivior Pharmaceuticals, Inc. (INDV): Investor Outlook With 45% Potential Upside - DirectorsTalk Interviews
Quantbot Technologies LP Makes New Investment in Indivior PLC $INDV - MarketBeat
Equities Analysts Issue Forecasts for Indivior Q4 Earnings - MarketBeat
Indivior Pharmaceuticals (INDV) Valuation Check After Strong Long Term Shareholder Returns - Sahm
Indivior’s Strong 2025 Results and US$400 Million Buyback Might Change The Case For Investing In Indivior Pharmaceuticals (INDV) - simplywall.st
Decoding Indivior Pharmaceuticals Inc (INDV): A Strategic SWOT I - GuruFocus
A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Its Recent Name Change - Yahoo Finance
Indivior Pharmaceuticals, Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Indivior (INDV) Q4 2025 Earnings Call Transcript - AOL.com
Indivior (NASDAQ:INDV) Announces Earnings Results - MarketBeat
INDVIndivior Pharmaceuticals Inc. Latest Stock News & Market Updates - Stock Titan
Indivior Pharmaceuticals Inc. (INDV) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Sector Update: Health Care - marketscreener.com
Indivior Q4 Earnings Call Highlights - Yahoo Finance
Indivior Q4 2025 slides: SUBLOCADE momentum drives earnings beat By Investing.com - Investing.com UK
Earnings call transcript: Indivior Q4 2025 beats expectations, stock rises - Investing.com
Indivior's Q4 Adjusted Earnings, Revenue Rise; Reaffirms 2026 Guidance - marketscreener.com
Indivior Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full-Year 2026 - marketscreener.com
Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Reports Q4 Revenue $358.0M, vs. FactSet Est of $305.6M - marketscreener.com
Indivior Reports Record 2025 Results, Launches Share Buyback - TipRanks
Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $0.82 per Share, vs. FactSet Est of $0.67 - marketscreener.com
Indivior Plc. Reports Increase In Q4 Bottom Line - Nasdaq
Indivior Pharmaceuticals : FINAL Indivior Corporate Investor Deck - marketscreener.com
Indivior Pharmaceuticals : FINAL Press Release - marketscreener.com
Indivior Pharmaceuticals : FINAL Indivior Q4 Financial Results Deck - marketscreener.com
Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results - The Manila Times
Indivior Returns to Havas With U.S. AOR Assignment - ADWEEK
Indivior Pharmaceuticals, Inc. (INDV) Investor Outlook: Strong Buy Ratings and 38% Upside Potential - DirectorsTalk Interviews
Indivior selects Havas U.S. integrated AOR - Medical Marketing and Media
Indivior to Participate in Upcoming Investor Conferences - The Manila Times
Is It Time To Reassess Indivior Pharmaceuticals (INDV) After Its 299% One Year Surge? - simplywall.st
Indivior PLC $INDV Shares Sold by Clark Estates Inc. NY - MarketBeat
Aberdeen Group plc Acquires New Position in Indivior PLC $INDV - MarketBeat
INDV SEC FilingsIndivior Pharmaceuticals Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Presents a High-Growth Momentum and Technical Setup Case - ChartMill
Persistent Asset Partners Ltd Acquires Shares of 58,409 Indivior PLC $INDV - MarketBeat
Indivior Pharmaceuticals to Report Q4 Earnings: What's in the Cards? - The Globe and Mail
Principal Financial Group Inc. Invests $1.70 Million in Indivior PLC $INDV - MarketBeat
Madison Avenue group discloses 5% Indivior (INDV) ownership in Schedule 13G/A - Stock Titan
Indivior Pharmaceuticals, Inc. (INDV) Investor Outlook: Navigating a 34.59% Potential Upside - DirectorsTalk Interviews
VELA International Fund's Indivior Pharmaceuticals Inc(INDV) Holding History - GuruFocus
INDV PE Ratio & Valuation, Is INDV Overvalued - Intellectia AI
Analysts Offer Insights on Healthcare Companies: Indivior (INDV) and NeoGenomics (NEO) - The Globe and Mail
Goldman Sachs (INDV) discloses 2.9% beneficial stake in Indivior - Stock Titan
New York State Common Retirement Fund Sells 56,140 Shares of Indivior PLC $INDV - MarketBeat
Indivior PLC (NASDAQ:INDV) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Indivior Pharmaceuticals (INDV) Stock Analysis: A 30% Upside Opportunity Amidst Promising Drug Innovations - DirectorsTalk Interviews
Federated Hermes Inc. Makes New $8.12 Million Investment in Indivior PLC $INDV - MarketBeat
How Opvee, Indivior’s powerful overdose antidote, went bust - statnews.com
Indivior Pharmaceuticals Inc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
1.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):